The prevention of viral recurrence in the long term
References (19)
- et al.
Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review
Hepatology
(2000) Prevention of recurrent hepatitis B post-liver transplantation
Liver Transpl
(2002)- et al.
Report of the Monothematic EASL Conference on liver transplantation in viral hepatitis
J Hepatol
(2006) - et al.
HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration
J Hepatol
(2007) - et al.
Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation
Gastroenterol-ogy
(2007) - et al.
Pharmacokinetics, efficacy and safety of intramuscular and intravenous of hepatitis B immunoglobulins combined with nucleoside analogues in prophylaxis of hepatitis B after liver transplantation
Dig Liver Dis
(2008) - et al.
Efficacy, safety and pharmacokinetic profile of pasteurized intramuscular anti-hepatitis B immunoglobulin for the prophylaxis of hepatitis B virus recurrence after liver transplantation
Dig Liver Dis
(2007) - et al.
Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy
Liver Transpl
(2008) - et al.
Liver transplantation: the Italian experience
Dig Liver Dis
(2002)
Cited by (14)
Common issues in the management of patients in the waiting list and after liver transplantation
2017, Digestive and Liver DiseaseCitation Excerpt :Risk factors associated with high rates of HBV reactivation are a high viral load prior to the transplant, HBeAg positivity, HIV co-infection, non-compliance, HCC at the time of the transplant, and drug resistance [41,42]. Hepatitis B immunoglobulins (HBIG) have been the core component of HBV prophylaxis since the landmark study by Samuel et al. in 1991, who showed that HBV recurrence could be prevented by the long-term administration of HBIG in 80% of non-viremic transplant patients [43,44]. When the first oral antiviral drug against HBV (Lamivudine) became available, antiviral monotherapy was attempted as an alternative, but failed to maintain results on a par with those achieved by HBIG in terms of HBV recurrence.
Management of HBV resistance in the post-transplant setting
2011, Digestive and Liver Disease SupplementsThe Green Tea Polyphenol, Epigallocatechin-3-Gallate (EGCG)-One Step Forward in Antiviral Therapy Against Hepatitis C Virus
2011, Journal of Clinical and Experimental HepatologyDoes pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIG and Nucleoside Analogues?
2011, Annals of HepatologyCitation Excerpt :The only patient in our cohort with an HBV-DNA level ≥ 105 IU/mL who received HBIg and LAM did not experience HBV recurrence. This contrasts with results from earlier reports1,34,35 but is similar those described in recent studies.24,28,29,36 Hence, the presence of viral replication should not be considered an absolute contraindication for liver transplantation if an adequate postoperative prophylaxis is used.28,29
Long-term care in orthotopic liver transplantation
2010, Italian Journal of Medicine